Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Centre, Open-Label, Phase II Study of Amogammadex Sodium as A Reversal Agent for Vecuronium Bromide or Rocuronium Bromide-Induced Moderate (at the Reappearance of T2) and Deep (PTC=1~2) Neuromuscular Blockade in Participants Undergoing ASA Grade 1-2 Elective Surgery

NCT07595393 is registered in ClinicalTrials.gov with Amckaus PTY LTD. as lead sponsor.

NCT NCT07595393
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07595393 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Centre, Open-Label, Phase II Study of Amogammadex Sodium as A Reversal Agent for Vecuronium Bromide or Rocuronium Bromide-Induced Moderate (at the Reappearance of T2) and Deep (PTC=1~2) Neuromuscular Blockade in Participants Undergoing ASA Grade 1-2 Elective Surgery
Lead sponsor
Amckaus PTY LTD.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
August 1, 2026
Completion date
December 30, 2027
Enrollment
64 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

reversing rocuronium-induced neuromuscular blockade in patients undergoing general anesthesia surgery, reversing vecuronium-induced neuromuscular blockade in patients undergoing general anesthesia surgery